| 000 | 01799 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517103742.0 | ||
| 264 | 0 | _c20170214 | |
| 008 | 201702s 0 0 eng d | ||
| 022 | _a1699-3055 | ||
| 024 | 7 |
_a10.1007/s12094-016-1524-y _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTsimafeyeu, I | |
| 245 | 0 | 0 |
_aFGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma. _h[electronic resource] |
| 260 |
_bClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico _cFeb 2017 |
||
| 300 |
_a265-268 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xmetabolism |
| 650 | 0 | 4 |
_aCarcinoma, Papillary _xmetabolism |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunoenzyme Techniques |
| 650 | 0 | 4 |
_aKidney Neoplasms _xmetabolism |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Grading |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aReceptor, Fibroblast Growth Factor, Type 2 _xmetabolism |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aKhasanova, A | |
| 700 | 1 | _aStepanova, E | |
| 700 | 1 | _aGordiev, M | |
| 700 | 1 | _aKhochenkov, D | |
| 700 | 1 | _aNaumova, A | |
| 700 | 1 | _aVarlamov, I | |
| 700 | 1 | _aSnegovoy, A | |
| 700 | 1 | _aDemidov, L | |
| 773 | 0 |
_tClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico _gvol. 19 _gno. 2 _gp. 265-268 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s12094-016-1524-y _zAvailable from publisher's website |
| 999 |
_c26192759 _d26192759 |
||